Prognostic Factors and Clinical Outcomes of High-Dose Chemotherapy followed by Autologous Stem Cell Transplantation in Patients with Peripheral T Cell Lymphoma, Unspecified: Complete Remission at Transplantation and the Prognostic Index of Peripheral T Cell Lymphoma Are the Major Factors Predictive of Outcome

Biology of Blood and Marrow Transplantation

Volumn 15, Issue 1, 2009, Pages 118-125

  Yang, Deok Hwan ^a   Kim, Won Seog ^b   Kim, Seok Jin ^c   Bae, Sung Hwa ^d   Kim, Sung Hyun ^e   Kim, In Ho ^f   Yoon, Sung Soo ^f   Mun, Yeung Chul ^g   Shin, Ho Jin ^h   Chae, Yee Soo ⁱ   Kwak, Jae Yong ^j   Kim, Hawk ^k   Kim, Min Kyoung ^l   Kim, Jin Seok ^m   Won, Jong Ho ⁿ   Lee, Je Jung ^a   Suh, Cheol Won ^o  

^a Chonnam National University Hwasun Hospital and Medical School   (South Korea)

^b Sungkyunkwan University School of Medicine   (South Korea)

^c Korea University Ansan Hospital   (South Korea)

^d Catholic University of Daegu   (South Korea)

^e Dong A Medical Center   (South Korea)

^f Seoul National University College of Medicine   (South Korea)

^g Ewha Womans University Medical Center   (South Korea)

^h Pusan National University School of Medicine   (South Korea)

ⁱ Kyungpook National University Hospital   (South Korea)

^j Chonbuk National University Medical School   (South Korea)

^k University of Ulsan College of Medicine   (South Korea)

^l Yeungnam University College of Medicine   (South Korea)

^m Yonsei University College of Medicine   (South Korea)

ⁿ Soonchunhyang University   (South Korea)

^o Asan Medical Center   (South Korea)

more..

Author keywords

Clinical outcomes; Peripheral T cell lymphoma; Prognostic factors; Unspecified

Indexed keywords

ALEMTUZUMAB; BLEOMYCIN; BUSULFAN; CARBOPLATIN; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FOLINIC ACID; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; LACTATE DEHYDROGENASE; MELPHALAN; METHOTREXATE; METHYLPREDNISOLONE; PREDNISOLONE; VINCRISTINE;

ADOLESCENT; ADULT; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER REGRESSION; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HIGH RISK POPULATION; HUMAN; KARNOFSKY PERFORMANCE STATUS; LACTATE DEHYDROGENASE BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PERIPHERAL T CELL LYMPHOMA; PROGNOSIS; RETROSPECTIVE STUDY; SOUTH KOREA; TREATMENT RESPONSE; WHOLE BODY RADIATION;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASIAN CONTINENTAL ANCESTRY GROUP; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOMA, T-CELL, PERIPHERAL; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 58149280205     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2008.11.010     Document Type: Article

References (34)

1. Cheng A.L., Chen Y.C., Wang C.H., et al. Direct comparisons of peripheral T-cell lymphoma with diffuse B-cell lymphoma of comparable histological grades-should peripheral T-cell lymphoma be considered separately?. J Clin Oncol 7 (1989) 725-731
2. Coiffier B., Brousse N., Peuchmaur M., et al. Peripheral T-cell lymphomas have a worse prognosis than B-cell lymphomas: a prospective study of 361 immunophenotyped patients treated with the LNH-84 regimen. The GELA (Groupe d'Etude des Lymphomes Agressives). Ann Oncol 1 (1990) 45-50
3. Kwak L.W., Wilson M., Weiss L.M., et al. Similar outcome of treatment of B-cell and T-cell diffuse large-cell lymphomas: the Stanford experience. J Clin Oncol 9 (1991) 1426-1431
4. Morabito F., Gallamini A., Stelitano C., et al. Clinical relevance of immunophenotype in a retrospective comparative study of 297 peripheral T-cell lymphomas, unspecified, and 496 diffuse large B-cell lymphomas: experience of the Intergruppo Italiano Linformi. Cancer 101 (2004) 1601-1608
5. Savage K.J., Harris N.L., Vose J.M., et al. ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. Blood 111 (2008) 5496-5504
6. Savage K.J., Chhanabhai M., Gascoyne R.D., and Connors J.M. Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification. Ann Oncol 15 (2004) 1467-1475
7. Kojima H., Hasegawa Y., Suzukawa K., et al. Clinicopathological features and prognostic factors of Japanese patients with "peripheral T-cell lymphoma, unspecified" diagnosed according to the WHO classification. Leuk Res 28 (2004) 1287-1292
8. Savage K.J. Aggressive peripheral T-cell lymphomas (specified and unspecified types). Hematology Am Soc Hematol Educ Program (2005) 267-277
9. Arrowsmith E.R., Macon W.R., Kinney M.C., et al. Peripheral T-cell lymphomas: clinical features and prognostic factors of 92 cases defined by the revised European American lymphoma classification. Leuk Lymphoma 44 (2003) 241-249
10. Zaja F., Russo D., Silvestri F., et al. Retrospective analysis of 23 cases with peripheral T-cell lymphoma, unspecified: clinical characteristics and outcome. Haematologica 82 (1997) 171-177
11. Rodriguez-Abreu D., Filho V.B., and Zucca E. Peripheral T-cell lymphomas, unspecified (or not otherwise specified): a review. Hematol Oncol 26 (2008) 8-20
12. Sonnen R., Schmidt W.P., Muller-Hermelink H.K., and Schmitz N. The International Prognostic Index determines the outcome of patients with nodal mature T-cell lymphomas. Br J Haematol 129 (2005) 366-372
13. Rodriguez J., Conde E., Gutierrez A., et al. The adjusted International Prognostic Index and beta-2-microglobulin predict the outcome after autologous stem cell transplantation in relapsing/refractory peripheral T-cell lymphoma. Haematologica 92 (2007) 1067-1074
14. Gallamini A., Stelitano C., Calvi R., et al. Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. Blood 103 (2004) 2474-2479
15. Haioun C., Lepage E., Gisselbrecht C., et al. Benefit of autologous bone marrow transplantation over sequential chemotherapy in poor-risk aggressive non-Hodgkin's lymphoma: updated results of the prospective study LNH87-2. Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 15 (1997) 1131-1137
16. Rodriguez J., Munsell M., Yazji S., et al. Impact of high-dose chemotherapy on peripheral T-cell lymphomas. J Clin Oncol 19 (2001) 3766-3770
17. Harris N.L., Jaffe E.S., Stein H., et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 84 (1994) 1361-1392
18. Cheson B.D., Horning S.J., Coiffier B., et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 17 (1999) 1244
19. Philip T., Guglielmi C., Hagenbeek A., et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 333 (1995) 1540-1545
20. Haioun C., Lepage E., Gisselbrecht C., et al. Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87-2 protocol-a groupe d'Etude des lymphomes de l'Adulte study. J Clin Oncol 18 (2000) 3025-3030
21. Jantunen E., and D'Amore F. Stem cell transplantation for peripheral T-cell lymphomas. Leuk Lymphoma 45 (2004) 441-446
22. Kewalramani T., Zelenetz A.D., Teruya-Feldstein J., et al. Autologous transplantation for relapsed or primary refractory peripheral T-cell lymphoma. Br J Haematol 134 (2006) 202-207
23. Smith S.D., Bolwell B.J., Rybicki L.A., et al. Autologous hematopoietic stem cell transplantation in peripheral T-cell lymphoma using a uniform high-dose regimen. Bone Marrow Transplant 40 (2007) 239-243
24. Rodriguez J., Caballero M.D., Gutierrez A., et al. High-dose chemotherapy and autologous stem cell transplantation in peripheral T-cell lymphoma: the GEL-TAMO experience. Ann Oncol 14 (2003) 1768-1775
25. Rodriguez J., Caballero M.D., Gutierrez A., et al. High dose chemotherapy and autologous stem cell transplantation in patients with peripheral T-cell lymphoma not achieving complete response after induction chemotherapy.The GEL-TAMO experience. Haematologica 88 (2003) 1372-1377
26. Kim M.K., Kim S., Lee S.S., et al. High-dose chemotherapy and autologous stem cell transplantation for peripheral T-cell lymphoma: complete response at transplant predicts survival. Ann Hematol 86 (2007) 435-442
27. Rodriguez J., Conde E., Gutierrez A., et al. The results of consolidation with autologous stem-cell transplantation in patients with peripheral T-cell lymphoma (PTCL) in first complete remission: the Spanish Lymphoma and Autologous Transplantation Group experience. Ann Oncol 18 (2007) 652-657
28. Rodriguez J., Conde E., Gutierrez A., et al. Frontline autologous stem cell transplantation in high-risk peripheral T-cell lymphoma: a prospective study from The Gel-Tamo Study Group. Eur J Haematol 79 (2007) 32-38
29. Chen A.I., McMillan A., Negrin R.S., et al. Long-term results of autologous hematopoietic cell transplantation for peripheral T cell lymphoma: the Stanford experience. Biol Blood Marrow Transplant 14 (2008) 741-747
30. Hamadani M., Awan F.T., Elder P., et al. Allogeneic hematopoietic stem cell transplantation for peripheral T cell lymphomas; evidence of graft-versus-T cell lymphoma effect. Biol Blood Marrow Transplant 14 (2008) 480-483
31. Doocey R.T., Toze C.L., Connors J.M., et al. Allogeneic haematopoietic stem-cell transplantation for relapsed and refractory aggressive histology non-Hodgkin lymphoma. Br J Haematol 131 (2005) 223-230
32. Le Gouill S., Milpied N., Buzyn A., et al. Graft-versus-lymphoma effect for aggressive T-cell lymphomas in adults: a study by the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire. J Clin Oncol 26 (2008) 2264-2271
33. Corradini P., Dodero A., Farina L., et al. Allogeneic stem cell transplantation following reduced-intensity conditioning can induce durable clinical and molecular remissions in relapsed lymphomas: pre-transplant disease status and histotype heavily influence outcome. Leukemia 21 (2007) 2316-2323
34. Corradini P., Dodero A., Zallio F., et al. Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin's lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells. J Clin Oncol 22 (2004) 2172-2176